Sustained Hyperparathyroidism Among Patients Treated With Lithium.

J Clin Psychopharmacol

Pharmacy Department Hospital Real de Nuestra Señora de Gracia Zaragoza, Spain Department Hospital Real de Nuestra Señora de Gracia Zaragoza, SpainATS-DUE, Psychiatry Department Hospital Real de Nuestra Señora de Gracia Zaragoza, SpainPsychiatry Department Hospital Universitario Miguel Servet Zaragoza, Spain.

Published: April 2016

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000473DOI Listing

Publication Analysis

Top Keywords

sustained hyperparathyroidism
4
hyperparathyroidism patients
4
patients treated
4
treated lithium
4
sustained
1
patients
1
treated
1
lithium
1

Similar Publications

Atraumatic bilateral femoral neck fractures are rare, especially in younger patients and those without significant comorbidities. However, pregnant individuals appear to be at increased risk due to normal physiological changes in calcium balance, leading to transient osteoporosis of the hip. In these individuals, calcium and bone mineral density are generally decreased, reflecting the calcium demands of the developing fetus.

View Article and Find Full Text PDF
Article Synopsis
  • Vitamin D plays a role in Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), particularly affecting secondary hyperparathyroidism in hemodialysis (HD) patients, and while cholecalciferol is recommended for vitamin D deficiency, its effects on CKD-MBD are not entirely clear.
  • An observational study involved 22 HD patients with vitamin D levels between 30-50 ng/mL receiving cholecalciferol to boost their levels above 75 ng/mL, comparing baseline biochemical markers with those at higher vitamin D levels.
  • The study found that 73% of participants achieved the target vitamin D level in about 7.5 weeks with a total dose of 525,000
View Article and Find Full Text PDF

A case series on parathyroid carcinoma: Diagnostic challenges and therapeutic approaches.

Int J Surg Case Rep

December 2024

Northeast Georgia Medical Center, Pathology Department, 743 Spring Street NE, Gainesville, GA 30501, United States of America. Electronic address:

Introduction: Parathyroid carcinoma is an exceptionally rare endocrine malignancy, constituting <1 % of primary hyperparathyroidism (PHPT) cases. It presents with more severe hypercalcemia and higher PTH levels than benign parathyroid diseases, requiring increased clinical awareness for accurate identification and specialized management. The results of this case series may provide insight into the clinical presentation, diagnostic workup, surgical management, and prognosis of parathyroid carcinoma, supplemented by a comprehensive review of current diagnostic and therapeutic approaches.

View Article and Find Full Text PDF

Secondary hyperparathyroidism (SHP) associated with chronic kidney disease (CKD) contributes to morbidity and mortality, yet the related parathyroid signaling pathways are not fully understood. Previous studies have indicated that the parathyroid mTORC1 pathway is activated in both experimental CKD and hypocalcemia-induced SHP. Furthermore, mice with parathyroid-specific mTOR deficiency (PT-mTOR) exhibit disrupted parathyroid glands, but maintain normal serum PTH levels.

View Article and Find Full Text PDF

Introduction: Secondary hyperparathyroidism (sHPT) is a common complication in patients with chronic kidney disease (CKD). Recently, etelcalcetide (EC), an intravenous calcimimetic, has been introduced as a treatment. We evaluated the efficacy of EC in treating sHPT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!